DRUG
Retatrutide
Administered SC
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Status
Active, not recruiting
Phase
Phase 3
Enrollment
643
Locations
53
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Interventions
Treatment arms and agents.
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
Mar 5, 2025
Study start
Mar 5, 2025
Primary completion
Apr 2028
Study completion
Apr 2028
Results posted
Not reported
Registry updated
Mar 3, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Week 0, Week 116
Secondary outcomes
Change from Baseline in Waist Circumference
Time frame · Week 0, Week 116
Percentage of Body Weight Reduction Achieved at Week 80 that is Maintained at Week 116
Time frame · Week 0, Week 80, Week 116
Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Time frame · Week 0, Week 116
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have obesity and a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity * Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening: * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening
Study locations
53 registered sites.
Canada · United Kingdom · United States. Showing up to 24 locations stored in the fast local snapshot.
Southern California Clinical Research
Santa Ana, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
CMR of Greater New Haven, LLC
Hamden, Connecticut, United States
ALL Medical Research, LLC
Cooper City, Florida, United States
Florida International Medical Research
Coral Gables, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Charter Research - Winter Park
Orlando, Florida, United States
Metabolic Research Institute, Inc.
West Palm Beach, Florida, United States
Kubost Clinical Research - Marietta
Marietta, Georgia, United States
North Georgia Clinical Research
Woodstock, Georgia, United States
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii, United States
Alliance for Multispecialty Research, LLC
Oak Brook, Illinois, United States
Springfield Clinic Main Campus
Springfield, Illinois, United States
Alliance for Multispecialty Research, LLC
Lexington, Kentucky, United States
L-MARC Research Center
Louisville, Kentucky, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Care Access - Lake Charles (Bayou Pines)
Lake Charles, Louisiana, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Alliance for Multispecialty Research, LLC
Kansas City, Missouri, United States
Vector Clinical Trials
Las Vegas, Nevada, United States
Dent Neurosciences Research Center, Inc
Amherst, New York, United States
Carteret Medical Group
Morehead City, North Carolina, United States
Care Access - Raleigh
Raleigh, North Carolina, United States
Tekton Research, LLC.
Moore, Oklahoma, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Retatrutide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly · Obesity · Cardiovascular Diseases
Phase 3
Completed
1,946
2026-07
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly · Type 2 Diabetes · Obesity
Phase 3
Completed
1,152
2026-07
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Eli Lilly · Obesity · Overweight
Phase 3
Active, not recruiting
586
2026-07
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Eli Lilly · Type 2 Diabetes
Phase 3
Active, not recruiting
320
2026-07
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly · Atherosclerotic Cardiovascular Disease (ASCVD) · Chronic Kidney Disease (CKD)
Phase 3
Active, not recruiting
10,000
2026-07
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Eli Lilly · Obesity
Phase 3
Active, not recruiting
800
2026-07
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly · Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase 3
Recruiting
4,500
2026-07
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Eli Lilly · Diabetes Mellitus · Insulin Sensitivity
Phase 1
Active, not recruiting
95
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.